Search clinical trials for: AR-102 0.01% Ophthalmic Solution

Total 2113 results

Aerie Pharmaceuticals

Completed

Ocular Hypotensive Efficacy of AR-102

Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Aerie Pharmaceuticals

Completed

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Allergan

Completed

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers

Healthy

United States
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Aerie Pharmaceuticals

Completed

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

Ocular Hypertension | Open Angle Glaucoma

United States
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Aerie Pharmaceuticals

Completed

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Dry Eye Syndromes

United States
Aerie Pharmaceuticals

Completed

A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

Healthy Subjects

United States
Allergan

Completed

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Ocular Hypertension | Glaucoma, Open-Angle

United States
Aerie Pharmaceuticals

Completed

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

Glaucoma

United States
VivaVision Biotech, Inc

Completed

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

Glaucoma, Open-Angle

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Alcon Research

Completed

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Corneal Scar

United States
Aurinia Pharmaceuticals Inc.

Completed

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome (AUDREY)

Keratoconjunctivitis Sicca | Dry Eye Syndrome

United States
Aerie Pharmaceuticals

Completed

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512 (COMET-4)

Dry Eye Disease

United States
Aerie Pharmaceuticals

Completed

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Aerie Pharmaceuticals

Completed

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Dry Eye Disease

United States
Aerie Pharmaceuticals

Completed

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-2)

Dry Eye Disease

United States
Alcon Research

Completed

A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye

Dry Eye
Allergan

Completed

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Eyelash Hypotrichosis

United States
SCAI Therapeutics

Completed

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Dry Eye Syndromes

Korea, Republic of
Qlaris Bio, Inc.

Not yet recruiting

Qlaris Phase 2 Study in NTG Patients

Glaucoma | Normal Tension Glaucoma (NTG) | Low-Tension Glaucoma, Bilateral | Low-Tension Glaucoma, Unspecified Eye

Korea, Republic of, Philippines
Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

24-hour Efficacy of AR-12286

Ocular Hypertension | Open Angle Glaucoma

United States
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Neurotrophic Keratitis

United States, Canada
Aldeyra Therapeutics, Inc.
ORA, Inc.

Completed

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Amneal Pharmaceuticals, LLC
CBCC Global Research

Recruiting

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Ocular Hypertension | Glaucoma, Open-Angle

United States
Mankind Pharma Limited
CBCC Global Research

Completed

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (Glaucoma)

Glaucoma, Open-Angle

United States
Allergan

Completed

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Aerie Pharmaceuticals

Completed

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Ocular Hypertension | Open Angle Glaucoma

United States
Laboratorios Sophia S.A de C.V.

Withdrawn

Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis (PRO-118)

Conjunctivitis, Allergic | Seasonal Allergic Conjunctivitis | Ocular Itching | Ocular Allergy | Perennial Allergic Conjunctivitis

Mexico
Allergan

Completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Austria
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland
Aldeyra Therapeutics, Inc.

Completed

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Non-infectious Anterior Uveitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Santen Pharmaceutical Co., Ltd.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

Japan
Aerie Pharmaceuticals

Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Aerie Pharmaceuticals

Completed

A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

Ocular Hypertension | Open-angle Glaucoma
Massachusetts Eye and Ear Infirmary

Completed

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

Cataract | Fuchs' Endothelial Dystrophy

United States
Allergan

Completed

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

Conjunctivitis, Allergic

Korea, Republic of

3

Subscribe